Prostaglandin-mediated analgesic pathway

The prostaglandin-mediated analgesic pathway is a complex biochemical cascade responsible for the synthesis and signaling of prostanoids that modulate pain, inflammation, and febrile responses [1]. The process begins with the release of arachidonic acid from cell membranes, which is then converted into prostaglandin H2 by the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) [2]. Specific synthases then produce various prostaglandins, most notably prostaglandin E2 (PGE2), which acts on G protein-coupled receptors (EP1-EP4) to sensitize peripheral nociceptors and enhance pain transmission in the central nervous system [2][3]. This pathway is the primary target for non-steroidal anti-inflammatory drugs (NSAIDs), which exert their analgesic effects by inhibiting COX enzymes and reducing the production of pro-inflammatory prostaglandins [1][4]. While highly effective for managing acute and chronic pain, pharmacological modulation of this pathway is associated with risks such as gastrointestinal irritation and cardiovascular events due to the physiological roles of prostaglandins in mucosal protection and vascular homeostasis [4][5].

Other names

Arachidonic acid cascadeProstanoid signaling pathwayCyclooxygenase pathwayCOX-PGE2 axis

Inhibition of cyclooxygenase enzymes (COX-1 and COX-2) to prevent the conversion of arachidonic acid into pro-inflammatory prostaglandins, thereby reducing nociceptor sensitization [1][2].